Invitrocue currently operates in Singapore, Australia, China, Hong Kong and Germany,
and is listed on Australian Securities Exchange under the ticker IVQ.
Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases.
In 2016, the company expanded its work in liver disease to the field of oncology. The technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine).
News & Events
Invitrocue’s Steven Fang: Insights into the Asian Biopharma Market
Invitrocue’s Steven Fang: Insights into the Asian Biopharma Market Published: Nov 29, 2018 By Mark Terry Steven Fang, Executive Director of Invitrocue It comes as no surprise to anyone that China is considered a big and booming potential market for drugs and medicines—or anything else, for that matter. The country has 1.3 billion people and a growing […]Read More
Health Investor Asia – The Serial Entrepreneur: Interview with Steven Fang
Originally published in Health Investor Asia – view PDF article here. Steven Fang understands how to set up a healthcare company. Not only is he chief executive and founder of ASX-listed oncology company Invitrocue, he was also the founder of Singapore-based Cordlife Group, a healthcare company which provides cord blood and cord lining banking services. […]Read More
Dr Lindner as Europe CEO and Prof Waugh as Senior Advisor
Dr Lindner as Europe CEO and Prof Waugh as Senior AdvisorRead More
Biotech Investment Summit @ Singapore
Date: 2nd November at 11.30am Venue: One Farrer Hotel, 1 Farrer Park Station Road, Singapore 217562 Dr Steven Fang will be speaking about “Strategic Investments in R/D to Accelerate Global Growth of Biotechnology Companies” detailing the following: Investment opportunities and partnerships in the Chronic disease segment Unique and advanced technologies showcase Expanding plan in Asia Co Located […]Read More
Symposium: “Oncology: The future of cancer treatment”
On the 1st of October, Invitrocue brought together international experts to discuss innovations in oncology and the potential of Onco-PDO as a disruptive diagnostic with KOLs. Invitrocue’s CEO Steven Fang and VP of Operations Martin Bach were joined by CEO of Invitrocue Europe Dr. Andreas Lindner, Prof Gopal Lyer from National Cancer Centre Singapore, Prof […]Read More
Assoc Prof Iyer as Chair of IVQ Medical Advisory Board
Assoc Prof Iyer as Chair of IVQ Medical Advisory BoardRead More
The 4th International Conference on Toxicity Testing Alternatives and Translational Toxicology & The 2nd Asian Congress on Alternatives @ Guangzhou
Date: October 11th, 2018; Thursday, Venue: Guangzhou Baiyun International Conference Center Prof Hanry Yu, co-founder of Invitrocue, will be giving a plenary presentation on: “Heterogeneity and solutions in cell-based models for in vitro toxicity testing applications”. Alternatives and translational toxicology have grown critically in modern toxicology and risk assessment. Meanwhile, alternatives are increasingly demanding for […]Read More